Lamotrigine Articles
LAMICTAL APPROVED FOR PEDIATRIC USE
23 May 1994
INTERIM PRETAX UP 12% AT WELLCOME
28 March 1994
ANALYSTS FORECAST FDA YEAR-END APPROVALS
13 December 1993
THE DAWN OF A NEW ERA FOR EPILEPSY
27 September 1993
DUPONT MERCK TO PROMOTE LAMICTAL
16 August 1993
WELLCOME NOT JUST AN ANTIVIRAL COMPANY?
19 July 1993
NEW HOPES FOR EPILEPSY TREATMENT
12 July 1993
WELLCOME R&D PIPELINE: PART 2
17 May 1993
NEUROPHARMACEUTICAL MARKET IN USA
19 April 1993
WELLCOME INTERIMS DRIVEN BY ZOVIRAX
29 March 1993
EUROPE STOCK COMMENT
29 March 1993
LAMICTAL BACKED BY FDA PANEL
29 March 1993
LAMICTAL TO BE REVIEWED BY FDA
21 December 1992
WELLCOME'S US "TIDAL WAVE" REVERSING?
21 December 1992
"EXCELLENT START" TO 1992 AT WELLCOME
27 January 1992
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
